Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small… Read more
Summit Therapeutics PLC (SMMT) - Total Assets
Latest total assets as of September 2025: $261.73 Million USD
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) holds total assets worth $261.73 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Summit Therapeutics PLC - Total Assets Trend (2003–2024)
This chart illustrates how Summit Therapeutics PLC’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Summit Therapeutics PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Summit Therapeutics PLC's total assets of $261.73 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.1% |
| Accounts Receivable | $557.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.86 Million | 0.4% |
Asset Composition Trend (2003–2024)
This chart illustrates how Summit Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Summit Therapeutics PLC's current assets represent 97.3% of total assets in 2024, a decrease from 100.0% in 2003.
- Cash Position: Cash and equivalents constituted 24.1% of total assets in 2024, down from 100.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 25.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.4% of total assets.
Summit Therapeutics PLC Competitors by Total Assets
Key competitors of Summit Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Summit Therapeutics PLC - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Summit Therapeutics PLC generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Summit Therapeutics PLC is currently not profitable relative to its asset base.
Summit Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.80 | 8.31 | 3.34 |
| Quick Ratio | 3.80 | 8.30 | 3.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $181.54 Million | $ 431.28 Million | $ 46.53 Million |
Summit Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Summit Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 57.93 |
| Latest Market Cap to Assets Ratio | 4.55 |
| Asset Growth Rate (YoY) | 114.6% |
| Total Assets | $435.56 Million |
| Market Capitalization | $1.98 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Summit Therapeutics PLC's assets at a significant premium ( 4.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Summit Therapeutics PLC's assets grew by 114.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Summit Therapeutics PLC (2003–2024)
The table below shows the annual total assets of Summit Therapeutics PLC from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $435.56 Million | +114.62% |
| 2023-12-31 | $202.95 Million | -69.44% |
| 2022-12-31 | $664.17 Million | +485.82% |
| 2021-12-31 | $113.37 Million | +10.61% |
| 2020-12-31 | $102.50 Million | +35.84% |
| 2019-12-31 | $75.46 Million | -3.74% |
| 2018-12-31 | $78.39 Million | +2.63% |
| 2017-12-31 | $76.38 Million | +62.58% |
| 2016-12-31 | $46.98 Million | +31.55% |
| 2015-12-31 | $35.71 Million | +22.20% |
| 2014-12-31 | $29.22 Million | +167.18% |
| 2013-12-31 | $10.94 Million | +58.21% |
| 2012-12-31 | $6.91 Million | +13.00% |
| 2011-12-31 | $6.12 Million | -24.06% |
| 2010-12-31 | $8.06 Million | -56.16% |
| 2009-12-31 | $18.38 Million | -8.54% |
| 2008-12-31 | $20.09 Million | -71.04% |
| 2007-12-31 | $69.38 Million | +49.39% |
| 2006-12-31 | $46.44 Million | +79.54% |
| 2005-12-31 | $25.87 Million | -3.76% |
| 2004-12-31 | $26.88 Million | +18314.66% |
| 2003-12-31 | $145.96K | -- |